IN2012DN01152A - 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-n-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide benzenesulfonate crystal of same crystal polymorph thereof and methods for production thereof - Google Patents

2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-n-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide benzenesulfonate crystal of same crystal polymorph thereof and methods for production thereof

Info

Publication number
IN2012DN01152A
IN2012DN01152A IN1152DEN2012A IN2012DN01152A IN 2012DN01152 A IN2012DN01152 A IN 2012DN01152A IN 1152DEN2012 A IN1152DEN2012 A IN 1152DEN2012A IN 2012DN01152 A IN2012DN01152 A IN 2012DN01152A
Authority
IN
India
Prior art keywords
compound
hydroxyacetyl
trifluoromethoxy
pyridinyl
thio
Prior art date
Application number
Other languages
English (en)
Inventor
Niwa Masashi
Deguchi Hiroshi
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of IN2012DN01152A publication Critical patent/IN2012DN01152A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
IN1152DEN2012 2009-07-17 2010-07-16 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-n-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide benzenesulfonate crystal of same crystal polymorph thereof and methods for production thereof IN2012DN01152A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009169130 2009-07-17
PCT/JP2010/062071 WO2011007870A1 (ja) 2009-07-17 2010-07-16 ２－［［［２－［（ヒドロキシアセチル）アミノ］－４－ピリジニル］メチル］チオ］－ｎ－［４－（トリフルオロメトキシ）フェニル］－３－ピリジンカルボキサミドのベンゼンスルホン酸塩、その結晶、その結晶多形およびそれらの製造方法

Publications (1)

Publication Number Publication Date
IN2012DN01152A true IN2012DN01152A (en) 2015-04-10

Family

ID=43449480

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1152DEN2012 IN2012DN01152A (en) 2009-07-17 2010-07-16 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-n-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide benzenesulfonate crystal of same crystal polymorph thereof and methods for production thereof

Country Status (17)

Country Link
US (4) US9029398B2 (zh)
EP (1) EP2455368B1 (zh)
JP (1) JP5662719B2 (zh)
KR (1) KR101710740B1 (zh)
CN (1) CN102471273B (zh)
AU (1) AU2010271746B2 (zh)
BR (1) BR112012001159A2 (zh)
CA (1) CA2767992C (zh)
EA (1) EA019689B1 (zh)
ES (1) ES2554360T3 (zh)
HK (2) HK1167644A1 (zh)
IN (1) IN2012DN01152A (zh)
MX (1) MX2012000749A (zh)
MY (1) MY157122A (zh)
NZ (1) NZ597495A (zh)
SG (1) SG177576A1 (zh)
WO (1) WO2011007870A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN06911A (zh) 2012-01-31 2015-05-15 Santen Pharmaceutical Co Ltd
MX2016003566A (es) 2013-09-20 2016-06-02 Santen Pharmaceutical Co Ltd Composicion que contiene polietilen glicol.
TW201609145A (zh) 2013-12-25 2016-03-16 參天製藥股份有限公司 注射劑及形成緩釋（ｄｅｐｏｔ）之方法
RU2726625C2 (ru) * 2015-03-17 2020-07-15 Сантен Фармасьютикал Ко., Лтд. Фармацевтическая композиция, включающая полипептид
WO2016148227A1 (ja) * 2015-03-18 2016-09-22 参天製薬株式会社 医薬組成物の安定保存
JP2016175900A (ja) * 2015-03-18 2016-10-06 参天製薬株式会社 徐放性医薬組成物
WO2016178900A1 (en) * 2015-05-01 2016-11-10 Odin Biotech Ocular implant for delivery of pyridinecarboxamide derivative

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4626353B2 (ja) * 2004-02-17 2011-02-09 参天製薬株式会社 置換又は無置換アミノ基を導入した４−ピリジルアルキルチオ基を有する新規環式化合物
ES2368153T3 (es) 2004-02-17 2011-11-14 Santen Pharmaceutical Co., Ltd. Nuevo compuesto cíclico que presenta un grupo 4-piridilalquiltio que presenta amino (no) sustituido introducido en el mismo.
NZ548949A (en) * 2004-02-17 2009-09-25 Santen Pharmaceutical Co Ltd Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein
WO2006106914A1 (ja) 2005-03-31 2006-10-12 Santen Pharmaceutical Co., Ltd. ピリミジニルアルキルチオ基を有する新規環式化合物
JP4834441B2 (ja) * 2005-03-31 2011-12-14 参天製薬株式会社 ピリミジニルアルキルチオ基を有する新規環式化合物

Also Published As

Publication number Publication date
ES2554360T3 (es) 2015-12-18
US20150291560A1 (en) 2015-10-15
MX2012000749A (es) 2012-01-27
US20170081286A1 (en) 2017-03-23
US20120116088A1 (en) 2012-05-10
NZ597495A (en) 2013-08-30
MY157122A (en) 2016-05-13
HK1167644A1 (zh) 2012-12-07
CN102471273B (zh) 2014-07-16
EA019689B1 (ru) 2014-05-30
CA2767992A1 (en) 2011-01-20
EA201200146A1 (ru) 2012-06-29
US9359328B2 (en) 2016-06-07
AU2010271746B2 (en) 2014-07-03
KR20130025857A (ko) 2013-03-12
EP2455368A1 (en) 2012-05-23
AU2010271746A1 (en) 2012-02-02
CA2767992C (en) 2017-03-21
JP5662719B2 (ja) 2015-02-04
KR101710740B1 (ko) 2017-02-27
EP2455368B1 (en) 2015-09-16
WO2011007870A1 (ja) 2011-01-20
US9902698B2 (en) 2018-02-27
BR112012001159A2 (pt) 2016-03-01
SG177576A1 (en) 2012-02-28
HK1167647A1 (zh) 2012-12-07
CN102471273A (zh) 2012-05-23
EP2455368A4 (en) 2013-01-09
US9029398B2 (en) 2015-05-12
JP2011037844A (ja) 2011-02-24
US20160251314A1 (en) 2016-09-01
US9546140B2 (en) 2017-01-17

Similar Documents

Publication Publication Date Title
IN2012DN01152A (en) 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-n-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide benzenesulfonate crystal of same crystal polymorph thereof and methods for production thereof
TW200738716A (en) Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
RS54677B1 (en) Crystalline Forms 4- [5- [3-Chloro-5- (Trifluoromethyl) phenyl] -4,5-dihydro-5- (trifluoromethyl) -3-isoxazolyl] -N- [2-oxo-2 - [(2, 2,2-TRIFLUOROETHYL) AMINO] ETHYL] -1-NAPHTHALENCARBOXAMIDE
UA84462C2 (ru) Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой
HK1204960A1 (zh) 高純度的 -或 -氟苄氧基 苄氨基 丙酰胺類及其用途
TWI370121B (en) Process for the preparation of a 2-pyridylethylcarboxamide derivative
UA94424C2 (en) 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors
TW200605881A (en) Substantially pure 2-{[2-(2-methylamino-pyrimidin-4-yl)-1H-indole-5-carbonyl]-amino}-3-(phenylpyridin-2-yl-amino)-propionic acid as an IκB kinase inhibitor
WO2011141933A3 (en) Process for preparation of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid and its pharmaceutically acceptable salts
PE20161369A1 (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona sustituidos con tetrazolona
IL183700A0 (en) Process for production of (4,5-dihydroisoxazol-3-yl)thio-carboxamidine salts
WO2009037485A1 (en) Antibacterial agents
EA201270099A1 (ru) Транс-4-[[(5s)-5-[[[3,5-бис(трифторметил)фенил]метил](2-метил-2h-тетразол-5-ил)амино]-2,3,4,5-тетрагидро-7,9-диметил-1h-1-бензазепин-1-ил]метил]циклогексанкарбоновая кислота
WO2008089436A3 (en) Crystalline forms of histone deacetylase inhibitors
NZ598693A (en) Maleic acid salt and crystal thereof
Robichaud et al. Rational design of potent and selective NH-linked aryl/heteroaryl cathepsin K inhibitors
MXPA05007847A (es) Derivados de acilaminotiazol, su preparacion y su utilizacion como inhibidores de la produccion de peptido beta-amiloide.
NZ587591A (en) Diarylthiazole derivatives such as tetomilast as mmp-2 and/or mmp-9 inhibitors
KR20230106605A (ko) Cd38의 헤테로아릴 아미드 억제제
MX2010002300A (es) Polimorfos de sal sodica del acido (3-(((4-terc-butil-bencil)-(pir idin-3-sulfonil)-amino)-metil)-fenoxi)-acetico o un hidrato de los mismos y procedimientos para fabricar los mismos.
IL216661A0 (en) Crystalline phases of 2'-{[2-(4-methoxy-phenyl)-acetylamino]-methyl}-biphenyl-2-carboxylic acid (2-pyridin-3-yl-ethyl)-amide
WO2008010089A3 (en) Process for preparation of intermediates of rosiglitazone, rosiglitazone and polymorphic forms thereof
TH145939A (th) รูปแบบที่เป็นผลึกของสารยับยั้งของการกระทำระหว่างกันของ MDM2/4 และ p53
BRPI0811995A2 (pt) " métodos de produção de cristais de ácido glutâmico de forma alfa e de produção de monoidrato de glutamato monossódico."
TH144014A (th) กรรมวิธีการผลิตสำหรับอนุพันธ์ไพริมิดีน